RayBiotech has signed a master services agreement with a West Coast-based biopharmaceutical company to provide custom services in the area of preclinical research diagnostic testing.
RayBiotech will leverage its antibody array diagnostics technologies to collect quantitative diagnostics information concerning key biochemical targets involved in human physiology and disease.
RayBiotech president COO and co-founder Rani Huang said the master service agreement will allow the company to exploit its antibody array diagnostics technologies in a services venue for the benefit of the partners.
"This agreement reflects our recently announced strategic focus on further expansion of our growth and development through a broadening of our portfolio of products and services, as well as, increased customer activities on a global basis," Huang added.
